Relay Therapeutics, Inc.
RLAY- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001812364
In the last 90 days, Relay Therapeutics, Inc. insiders filed 0 open-market purchases and 14 sales; 259 institutions reported holding it in 13F filings for Q2 2026, worth $4.58B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q3 2024
Institutional positions in Relay Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 195
- +18 vs. Q2 2024
- Shares held
- 163.4M
- +47.2M (+40.6%) vs. Q2 2024
- Total value
- $1.16B
- +$399.0M (+52.7%) vs. Q2 2024
- New holders
- 46
- 72 more added
- Sold out
- 28
- 46 more reduced
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RLAY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 259 | $4.58B |
| Q1 2026 | 244 | $1.83B |
| Q4 2025 | 227 | $1.47B |
| Q3 2025 | 199 | $867.4M |
| Q2 2025 | 208 | $591.8M |
| Q1 2025 | 208 | $438.1M |
| Q4 2024 | 200 | $675.8M |
| Q3 2024 | 195 | $1.16B |
| Q2 2024 | 179 | $826.8M |
| Q1 2024 | 189 | $1.10B |
| Q4 2023 | 177 | $1.40B |
| Q3 2023 | 172 | $1.10B |
| Q2 2023 | 161 | $1.64B |
| Q1 2023 | 157 | $2.16B |
| Q4 2022 | 165 | $1.91B |
| Q3 2022 | 162 | $2.76B |
| Q2 2022 | 148 | $2.02B |
| Q1 2022 | 140 | $3.38B |
| Q4 2021 | 131 | $3.41B |
| Q3 2021 | 132 | $2.89B |
| Q2 2021 | 125 | $3.26B |
| Q1 2021 | 137 | $2.96B |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Relay Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −156,254−100.0% | Sold out |
| Schroder Investment Management Group | 0 | $0 | 0.00% | −153,769−100.0% | Sold out |
| Caxton Associates LP | 0 | $0 | 0.00% | −107,568−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −105,518−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | −101,365−100.0% | Sold out |
| Wellington Management Group LLP | 0 | $0 | 0.00% | −71,913−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −65,989−100.0% | Sold out |
| Royce & Associates LP | 0 | $0 | 0.00% | −48,381−100.0% | Sold out |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −46,702−100.0% | Sold out |
| Capstone Investment Advisors, LLC | 0 | $0 | 0.00% | −44,511−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −43,900−100.0% | Sold out |
| Pennant Investors, LP | 0 | $0 | 0.00% | −42,400−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −14,580−100.0% | Sold out |
| Vontobel Holding Ltd. | 0 | $0 | 0.00% | −14,432−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −2,500−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −1,103−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −645−100.0% | Sold out |
| Wetzel Investment Advisors, Inc. | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −624−100.0% | Sold out |
| Versant Capital Management, Inc | 0 | $0 | 0.00% | −309−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −52−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −14−100.0% | Sold out |
| TFC Financial Management | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |
| Susquehanna Fundamental Investments, LLC | – | – | – | – | Not filed |